{"abstract":"On May 29, 2026, the United States Food and Drug Administration (FDA) approved a new drug application for Cypsedo (cipepofol) for induction of general anesthesia in adults undergoing surgery. The Department of Health and Human Services provided the Drug Enforcement Administration (DEA) with a scheduling recommendation to place cipepofol, chemically known as 2-[(1R)-1-cyclopropylethyl]-6- isopropylphenol, in schedule IV of the Controlled Substances Act (CSA). In accordance with the CSA, as amended by the Improving Regulatory Transparency for New Medical Therapies Act, DEA is hereby issuing an interim final rule placing cipepofol in schedule IV of the CSA.","action":"Interim final rule; request for comments.","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2026/08/27/2026-17536.html","cfr_references":[{"chapter":null,"citation_url":null,"part":"1308","title":21}],"citation":"91 FR 55259","comment_url":null,"comments_close_on":"2026-09-28","correction_of":null,"corrections":[],"dates":"This rule is effective August 27, 2026. Comments must be submitted electronically or postmarked on or before September 28, 2026. The electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.","disposition_notes":null,"docket_ids":["Docket No. DEA 1713"],"dockets":[{"supporting_documents":[{"title":"HHS Cipepofol 8FA Report May2026","document_id":"DEA-2026-1519-0004"},{"title":"ASH to DEA- Cipepofol-May2026","document_id":"DEA-2026-1519-0003"},{"title":"DEA-1713_8 Factor Analysis_Cipepofol_August 2026","document_id":"DEA-2026-1519-0002"}],"agency_name":"DEA","documents":[{"comment_count":5,"comment_start_date":"2026-08-27","updated_at":"2026-09-29T00:13:31.237-04:00","comment_url":"https://www.regulations.gov/commenton/DEA-2026-1519-0001","allow_late_comments":false,"id":"DEA-2026-1519-0001","comment_end_date":"2026-09-29","regulations_dot_gov_open_for_comment":false}],"supporting_documents_count":3,"id":"DEA-2026-1519","title":"Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV  (DEA1713)"}],"document_number":"2026-17536","effective_on":"2026-08-27","end_page":55265,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2026/08/27/2026-17536.xml","html_url":"https://www.federalregister.gov/documents/2026/08/27/2026-17536/schedules-of-controlled-substances-placement-of-cipepofol-in-schedule-iv","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2026-17536?publication_date=2026-08-27","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2026-08-27/2026-17536/mods.xml","not_received_for_publication":null,"page_length":7,"page_views":{"count":894,"last_updated":"2026-10-23 14:15:06 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-08-27/pdf/2026-17536.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-17536.pdf?1787688907","publication_date":"2026-08-27","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2026/08/27/2026-17536.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"supporting_documents":[{"title":"HHS Cipepofol 8FA Report May2026","document_id":"DEA-2026-1519-0004"},{"title":"ASH to DEA- Cipepofol-May2026","document_id":"DEA-2026-1519-0003"},{"title":"DEA-1713_8 Factor Analysis_Cipepofol_August 2026","document_id":"DEA-2026-1519-0002"}],"comments_count":5,"agency_id":"DEA","comments_url":"https://www.regulations.gov/docketBrowser?rpp=50&so=DESC&sb=postedDate&po=0&dct=PS&D=DEA-2026-1519","supporting_documents_count":3,"docket_id":"DEA-2026-1519","document_id":"DEA-2026-1519-0001","regulation_id_number":null,"title":"Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV  (DEA1713)","checked_regulationsdotgov_at":"2026-09-29T08:55:03Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":55259,"subtype":null,"title":"Schedules of Controlled Substances: Placement of Cipepofol in Schedule IV","toc_doc":"Placement of Cipepofol in Schedule IV","toc_subject":"Schedules of Controlled Substances","topics":["Administrative practice and procedure","Drug traffic control","Reporting and recordkeeping requirements"],"type":"Rule","volume":91}